

October 31, 2006

AnGes MG, Inc.

AnGes MG Launches Phase II Clinical Trials of NF- κ B Decoy Oligo in the Treatment of Atopic Dermatitis in Japan

AnGes MG has been preparing phase II clinical trials of NF- κ B decoy oligo and is now pleased to announce that the trial has been launched as the drug was administered to the trial participants.

NF- κ B decoy oligo is being developed as a nucleic acid drug indicated for immuno-inflammatory diseases such as atopic dermatitis and rheumatoid arthritis. Of these, atopic dermatitis is a disease for which the development of a new treatment drug is eagerly awaited, since, although there are believed to be as many as 1.4 million patients in Japan, effective treatment methods have yet to be developed.

NF- κ B decoy oligo, because of its characteristic of specifically suppressing transcription factors, has the potential to become an epoch-making atopic dermatitis drug that is effective and induces few adverse reactions, and therefore AnGes MG has been stepping up the clinical development of this drug in Japan.

The Phase II clinical trials are carried out in patients with atopic dermatitis of moderate or severer lesions on the face to investigate efficacy and safety of application of NF- κ B decoy oligo ointment and to find its optimal dose.

Development in Japan of NF- κ B decoy oligo used in the treatment of atopic dermatitis is being carried out in alliance with Alfresa Pharma Corporation.

<Reference>

Development Status of NF- κ B Decoy Oligo

| Field of indications | Region | Development Phase | Licensee |
|-----------------------------------|--------|----------------------------------|----------------------------|
| Atopic dermatitis | Japan | <u>Phase II clinical trial</u> | Alfresa Pharma Corporation |
| Psoriasis | | Preclinical | Undecided |
| Rheumatoid arthritis | | Clinical trial under preparation | Undecided |
| Osteoarthritis | | Preclinical | Undecided |
| Prevention of vascular restenosis | | Clinical trial under preparation | Goodman Co., Ltd. |

Note: The underlined item is the updated topic.